<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac&amp;utm_campaign=pubmed-2&amp;ff=20231204212342&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac&amp;utm_campaign=pubmed-2&amp;ff=20231204212342&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Tue, 05 Dec 2023 02:23:44 +0000</lastbuilddate>
<pubDate>Mon, 04 Dec 2023 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>From the Literature</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38048410/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231204212342&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 29;148(9):798-799. doi: 10.1161/CIRCULATIONAHA.123.066278. Epub 2023 Aug 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38048410/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231204212342&v=2.17.9.post6+86293ac">38048410</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066278>10.1161/CIRCULATIONAHA.123.066278</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38048410</guid>
<pubDate>Mon, 04 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Tracy Hampton</dc:creator>
<dc:date>2023-12-04</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>From the Literature</dc:title>
<dc:identifier>pmid:38048410</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066278</dc:identifier>
</item>
<item>
<title>Correction to: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38048397/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231204212342&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Dec 5;148(23):e186. doi: 10.1161/CIR.0000000000001195. Epub 2023 Dec 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38048397/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231204212342&v=2.17.9.post6+86293ac">38048397</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001195>10.1161/CIR.0000000000001195</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38048397</guid>
<pubDate>Mon, 04 Dec 2023 06:00:00 -0500</pubDate>
<dc:date>2023-12-04</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines</dc:title>
<dc:identifier>pmid:38048397</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001195</dc:identifier>
</item>
<item>
<title>Response by Nademanee et al to Letter Regarding Article, "Long-Term Outcomes of Brugada Substrate Ablation: A Report From BRAVO (Brugada Ablation of VF Substrate Ongoing Multicenter Registry)"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38048396/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231204212342&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Dec 5;148(23):1915-1916. doi: 10.1161/CIRCULATIONAHA.123.066505. Epub 2023 Dec 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38048396/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231204212342&v=2.17.9.post6+86293ac">38048396</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066505>10.1161/CIRCULATIONAHA.123.066505</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38048396</guid>
<pubDate>Mon, 04 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Koonlawee Nademanee</dc:creator>
<dc:creator>Michel Haissaguerre</dc:creator>
<dc:creator>Arthur A M Wilde</dc:creator>
<dc:creator>Elijah Behr</dc:creator>
<dc:creator>Akihiko Nogami</dc:creator>
<dc:creator>BRAVO Investigators</dc:creator>
<dc:date>2023-12-04</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Nademanee et al to Letter Regarding Article, "Long-Term Outcomes of Brugada Substrate Ablation: A Report From BRAVO (Brugada Ablation of VF Substrate Ongoing Multicenter Registry)"</dc:title>
<dc:identifier>pmid:38048396</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066505</dc:identifier>
</item>
<item>
<title>ALPK3 Functions as a Pseudokinase</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38048395/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231204212342&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Dec 5;148(23):1911-1913. doi: 10.1161/CIRCULATIONAHA.123.065993. Epub 2023 Dec 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38048395/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231204212342&v=2.17.9.post6+86293ac">38048395</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065993>10.1161/CIRCULATIONAHA.123.065993</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38048395</guid>
<pubDate>Mon, 04 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Wei Feng</dc:creator>
<dc:creator>Julius Bogomolovas</dc:creator>
<dc:creator>Li Wang</dc:creator>
<dc:creator>Mengchen Li</dc:creator>
<dc:creator>Ju Chen</dc:creator>
<dc:date>2023-12-04</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>ALPK3 Functions as a Pseudokinase</dc:title>
<dc:identifier>pmid:38048395</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065993</dc:identifier>
</item>
<item>
<title>Letter by Kataoka et al Regarding Article, "Long-Term Outcomes of Brugada Substrate Ablation: A Report From BRAVO (Brugada Ablation of VF Substrate Ongoing Multicenter Registry)"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38048394/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231204212342&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Dec 5;148(23):1914. doi: 10.1161/CIRCULATIONAHA.123.065320. Epub 2023 Dec 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38048394/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231204212342&v=2.17.9.post6+86293ac">38048394</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065320>10.1161/CIRCULATIONAHA.123.065320</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38048394</guid>
<pubDate>Mon, 04 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Naoya Kataoka</dc:creator>
<dc:creator>Teruhiko Imamura</dc:creator>
<dc:creator>Koichiro Kinugawa</dc:creator>
<dc:date>2023-12-04</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Kataoka et al Regarding Article, "Long-Term Outcomes of Brugada Substrate Ablation: A Report From BRAVO (Brugada Ablation of VF Substrate Ongoing Multicenter Registry)"</dc:title>
<dc:identifier>pmid:38048394</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065320</dc:identifier>
</item>
<item>
<title>A Story With an Interesting Twist</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38048393/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231204212342&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Dec 5;148(23):1907-1910. doi: 10.1161/CIRCULATIONAHA.123.067296. Epub 2023 Dec 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38048393/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231204212342&v=2.17.9.post6+86293ac">38048393</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067296>10.1161/CIRCULATIONAHA.123.067296</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38048393</guid>
<pubDate>Mon, 04 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Chan-Hee Lee</dc:creator>
<dc:creator>Melvin M Scheinman</dc:creator>
<dc:date>2023-12-04</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A Story With an Interesting Twist</dc:title>
<dc:identifier>pmid:38048393</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067296</dc:identifier>
</item>
<item>
<title>Role of Polyunsaturated Fat in Modifying Cardiovascular Risk Associated With Family History of Cardiovascular Disease: Pooled De Novo Results From 15 Observational Studies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38047387/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231204212342&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: A significant interaction between biomarkers of low EPA/DHA intake, but not the other PUFA, and a family history was observed. This novel finding might suggest a need to emphasize the benefit of consuming oily fish for individuals with a family history of CVD.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Dec 4. doi: 10.1161/CIRCULATIONAHA.123.065530. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: It is unknown whether dietary intake of polyunsaturated fatty acids (PUFA) modifies the cardiovascular disease (CVD) risk associated with a family history of CVD. We assessed interactions between biomarkers of low PUFA intake and a family history in relation to long-term CVD risk in a large consortium.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Blood and tissue PUFA data from 40 885 CVD-free adults were assessed. PUFA levels ≤25th percentile were considered to reflect low intake of linoleic, alpha-linolenic, and eicosapentaenoic/docosahexaenoic acids (EPA/DHA). Family history was defined as having ≥1 first-degree relative who experienced a CVD event. Relative risks with 95% CI of CVD were estimated using Cox regression and meta-analyzed. Interactions were assessed by analyzing product terms and calculating relative excess risk due to interaction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: After multivariable adjustments, a significant interaction between low EPA/DHA and family history was observed (product term pooled RR, 1.09 [95% CI, 1.02-1.16]; <i>P</i>=0.01). The pooled relative risk of CVD associated with the combined exposure to low EPA/DHA, and family history was 1.41 (95% CI, 1.30-1.54), whereas it was 1.25 (95% CI, 1.16-1.33) for family history alone and 1.06 (95% CI, 0.98-1.14) for EPA/DHA alone, compared with those with neither exposure. The relative excess risk due to interaction results indicated no interactions.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: A significant interaction between biomarkers of low EPA/DHA intake, but not the other PUFA, and a family history was observed. This novel finding might suggest a need to emphasize the benefit of consuming oily fish for individuals with a family history of CVD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38047387/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231204212342&v=2.17.9.post6+86293ac">38047387</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065530>10.1161/CIRCULATIONAHA.123.065530</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38047387</guid>
<pubDate>Mon, 04 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>F Laguzzi</dc:creator>
<dc:creator>A Åkesson</dc:creator>
<dc:creator>M Marklund</dc:creator>
<dc:creator>F Qian</dc:creator>
<dc:creator>B Gigante</dc:creator>
<dc:creator>T M Bartz</dc:creator>
<dc:creator>J K Bassett</dc:creator>
<dc:creator>A Birukov</dc:creator>
<dc:creator>H Campos</dc:creator>
<dc:creator>Y Hirakawa</dc:creator>
<dc:creator>F Imamura</dc:creator>
<dc:creator>S Jäger</dc:creator>
<dc:creator>M Lankinen</dc:creator>
<dc:creator>R A Murphy</dc:creator>
<dc:creator>M Senn</dc:creator>
<dc:creator>T Tanaka</dc:creator>
<dc:creator>N Tintle</dc:creator>
<dc:creator>J K Virtanen</dc:creator>
<dc:creator>K Yamagishi</dc:creator>
<dc:creator>M Allison</dc:creator>
<dc:creator>I A Brouwer</dc:creator>
<dc:creator>U De Faire</dc:creator>
<dc:creator>G Eiriksdottir</dc:creator>
<dc:creator>L Ferrucci</dc:creator>
<dc:creator>N G Forouhi</dc:creator>
<dc:creator>J M Geleijnse</dc:creator>
<dc:creator>A M Hodge</dc:creator>
<dc:creator>H Kimura</dc:creator>
<dc:creator>M Laakso</dc:creator>
<dc:creator>U Risérus</dc:creator>
<dc:creator>A C van Westing</dc:creator>
<dc:creator>S Bandinelli</dc:creator>
<dc:creator>A Baylin</dc:creator>
<dc:creator>G G Giles</dc:creator>
<dc:creator>V Gudnason</dc:creator>
<dc:creator>H Iso</dc:creator>
<dc:creator>R N Lemaitre</dc:creator>
<dc:creator>T Ninomiya</dc:creator>
<dc:creator>W S Post</dc:creator>
<dc:creator>B M Psaty</dc:creator>
<dc:creator>J T Salonen</dc:creator>
<dc:creator>M B Schulze</dc:creator>
<dc:creator>M Y Tsai</dc:creator>
<dc:creator>M Uusitupa</dc:creator>
<dc:creator>N J Wareham</dc:creator>
<dc:creator>S W Oh</dc:creator>
<dc:creator>A C Wood</dc:creator>
<dc:creator>W S Harris</dc:creator>
<dc:creator>D Siscovick</dc:creator>
<dc:creator>D Mozaffarian</dc:creator>
<dc:creator>K Leander</dc:creator>
<dc:creator>Fatty Acids and Outcomes Research Consortium (FORCE)</dc:creator>
<dc:date>2023-12-04</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Role of Polyunsaturated Fat in Modifying Cardiovascular Risk Associated With Family History of Cardiovascular Disease: Pooled De Novo Results From 15 Observational Studies</dc:title>
<dc:identifier>pmid:38047387</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065530</dc:identifier>
</item>
<item>
<title>CD4+ T-Cell Legumain Deficiency Attenuates Hypertensive Damage via Preservation of TRAF6</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38047378/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231204212342&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: LGMN deficiency in T cells prevents hypertension and its complications by promoting Treg differentiation and function. Specifically targeting LGMN in Tregs may be an innovative approach for hypertension treatment.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Dec 4. doi: 10.1161/CIRCRESAHA.123.322835. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: T cells are central to the immune responses contributing to hypertension. LGMN (legumain) is highly expressed in T cells; however, its role in the pathogenesis of hypertension remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Peripheral blood samples were collected from patients with hypertension, and CD4+ T cells were sorted for gene expression and Western blotting analysis. TLGMNKO (T cell-specific LGMN-knockout) mice (Lgmn<sup>f/f</sup>/CD4<sup>Cre</sup>), regulatory T cell (Treg)-specific LGMN-knockout mice (Lgmn<sup>f/f</sup>/Foxp3<sup>YFP Cre</sup>), and RR-11a (LGMN inhibitor)-treated C57BL/6 mice were infused with Ang II (angiotensin II) or deoxycorticosterone acetate/salt to establish hypertensive animal models. Flow cytometry, 4-dimensional label-free proteomics, coimmunoprecipitation, Treg suppression, and in vivo Treg depletion or adoptive transfer were used to delineate the functional importance of T-cell LGMN in hypertension development.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: LGMN mRNA expression was increased in CD4+ T cells isolated from hypertensive patients and mice, was positively correlated with both systolic and diastolic blood pressure, and was negatively correlated with serum IL (interleukin)-10 levels. TLGMNKO mice exhibited reduced Ang II-induced or deoxycorticosterone acetate/salt-induced hypertension and target organ damage relative to WT (wild-type) mice. Genetic and pharmacological inhibition of LGMN blocked Ang II-induced or deoxycorticosterone acetate/salt-induced immunoinhibitory Treg reduction in the kidneys and blood. Anti-CD25 antibody depletion of Tregs abolished the protective effects against Ang II-induced hypertension in TLGMNKO mice, and LGMN deletion in Tregs prevented Ang II-induced hypertension in mice. Mechanistically, endogenous LGMN impaired Treg differentiation and function by directly interacting with and facilitating the degradation of TRAF6 (tumor necrosis factor receptor-associated factor 6) via chaperone-mediated autophagy, thereby inhibiting NF-κB (nuclear factor kappa B) activation. Adoptive transfer of LGMN-deficient Tregs reversed Ang II-induced hypertension, whereas depletion of TRAF6 in LGMN-deficient Tregs blocked the protective effects.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: LGMN deficiency in T cells prevents hypertension and its complications by promoting Treg differentiation and function. Specifically targeting LGMN in Tregs may be an innovative approach for hypertension treatment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38047378/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231204212342&v=2.17.9.post6+86293ac">38047378</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.322835>10.1161/CIRCRESAHA.123.322835</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38047378</guid>
<pubDate>Mon, 04 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Yuhu He</dc:creator>
<dc:creator>Pu Zou</dc:creator>
<dc:creator>Junmi Lu</dc:creator>
<dc:creator>Yufei Lu</dc:creator>
<dc:creator>Shuguang Yuan</dc:creator>
<dc:creator>Xialei Zheng</dc:creator>
<dc:creator>Jing Liu</dc:creator>
<dc:creator>Cheng Zeng</dc:creator>
<dc:creator>Ling Liu</dc:creator>
<dc:creator>Liang Tang</dc:creator>
<dc:creator>Zhenfei Fang</dc:creator>
<dc:creator>Xinqun Hu</dc:creator>
<dc:creator>Qiming Liu</dc:creator>
<dc:creator>Shenghua Zhou</dc:creator>
<dc:date>2023-12-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>CD4+ T-Cell Legumain Deficiency Attenuates Hypertensive Damage via Preservation of TRAF6</dc:title>
<dc:identifier>pmid:38047378</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.322835</dc:identifier>
</item>
<item>
<title>Update on Cardiovascular Implantable Electronic Device Infections and Their Prevention, Diagnosis, and Management: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38047353/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231204212342&amp;v=2.17.9.post6+86293ac
      <description>The American Heart Association sponsored the first iteration of a scientific statement that addressed all aspects of cardiovascular implantable electronic device infection in 2010. Major advances in the prevention, diagnosis, and management of these infections have occurred since then, necessitating a scientific statement update. An 11-member writing group was identified and included recognized experts in cardiology and infectious diseases, with a career focus on cardiovascular infections. The...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Dec 4. doi: 10.1161/CIR.0000000000001187. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The American Heart Association sponsored the first iteration of a scientific statement that addressed all aspects of cardiovascular implantable electronic device infection in 2010. Major advances in the prevention, diagnosis, and management of these infections have occurred since then, necessitating a scientific statement update. An 11-member writing group was identified and included recognized experts in cardiology and infectious diseases, with a career focus on cardiovascular infections. The group initially met in October 2022 to develop a scientific statement that was drafted with front-line clinicians in mind and focused on providing updated clinical information to enhance outcomes of patients with cardiovascular implantable electronic device infection. The current scientific statement highlights recent advances in prevention, diagnosis, and management, and how they may be incorporated in the complex care of patients with cardiovascular implantable electronic device infection.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38047353/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231204212342&v=2.17.9.post6+86293ac">38047353</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001187>10.1161/CIR.0000000000001187</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38047353</guid>
<pubDate>Mon, 04 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Larry M Baddour</dc:creator>
<dc:creator>Zerelda Esquer Garrigos</dc:creator>
<dc:creator>M Rizwan Sohail</dc:creator>
<dc:creator>Eva Havers-Borgersen</dc:creator>
<dc:creator>Andrew D Krahn</dc:creator>
<dc:creator>Vivian H Chu</dc:creator>
<dc:creator>Connie S Radke</dc:creator>
<dc:creator>Jennifer Avari-Silva</dc:creator>
<dc:creator>Mikhael F El-Chami</dc:creator>
<dc:creator>Jose M Miro</dc:creator>
<dc:creator>Daniel C DeSimone</dc:creator>
<dc:creator>American Heart Association Council on Lifelong Congenital Heart Disease and Heart Health in the Young (Young Hearts); and Council on Clinical Cardiology</dc:creator>
<dc:date>2023-12-04</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Update on Cardiovascular Implantable Electronic Device Infections and Their Prevention, Diagnosis, and Management: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:38047353</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001187</dc:identifier>
</item>
<item>
<title>2023 Atrial Fibrillation Guideline-at-a-Glance</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38043044/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231204212342&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 23:S0735-1097(23)07853-1. doi: 10.1016/j.jacc.2023.10.021. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38043044/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231204212342&v=2.17.9.post6+86293ac">38043044</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.021>10.1016/j.jacc.2023.10.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38043044</guid>
<pubDate>Sun, 03 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Barbara S Wiggins</dc:creator>
<dc:creator>ACC Solution Set Oversight Committee</dc:creator>
<dc:creator>Morgane Cibotti-Sun</dc:creator>
<dc:creator>Mykela M Moore</dc:creator>
<dc:date>2023-12-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>2023 Atrial Fibrillation Guideline-at-a-Glance</dc:title>
<dc:identifier>pmid:38043044</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.021</dc:identifier>
</item>
<item>
<title>2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38043043/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231204212342&amp;v=2.17.9.post6+86293ac
      <description>AIM: The "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Patients With Atrial Fibrillation" provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 23:S0735-1097(23)06465-3. doi: 10.1016/j.jacc.2023.08.017. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">AIM: The "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Patients With Atrial Fibrillation" provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A comprehensive literature search was conducted from May 12, 2022, to November 3, 2022, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through November 2022, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">STRUCTURE: Atrial fibrillation is the most sustained common arrhythmia, and its incidence and prevalence are increasing in the United States and globally. Recommendations from the "2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation" and the "2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation" have been updated with new evidence to guide clinicians. In addition, new recommendations addressing atrial fibrillation and thromboembolic risk assessment, anticoagulation, left atrial appendage occlusion, atrial fibrillation catheter or surgical ablation, and risk factor modification and atrial fibrillation prevention have been developed.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38043043/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231204212342&v=2.17.9.post6+86293ac">38043043</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.017>10.1016/j.jacc.2023.08.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38043043</guid>
<pubDate>Sun, 03 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Writing Committee Members</dc:creator>
<dc:creator>José A Joglar</dc:creator>
<dc:creator>Mina K Chung</dc:creator>
<dc:creator>Anastasia L Armbruster</dc:creator>
<dc:creator>Emelia J Benjamin</dc:creator>
<dc:creator>Janice Y Chyou</dc:creator>
<dc:creator>Edmond M Cronin</dc:creator>
<dc:creator>Anita Deswal</dc:creator>
<dc:creator>Lee L Eckhardt</dc:creator>
<dc:creator>Zachary D Goldberger</dc:creator>
<dc:creator>Rakesh Gopinathannair</dc:creator>
<dc:creator>Bulent Gorenek</dc:creator>
<dc:creator>Paul L Hess</dc:creator>
<dc:creator>Mark Hlatky</dc:creator>
<dc:creator>Gail Hogan</dc:creator>
<dc:creator>Chinwe Ibeh</dc:creator>
<dc:creator>Julia H Indik</dc:creator>
<dc:creator>Kazuhiko Kido</dc:creator>
<dc:creator>Fred Kusumoto</dc:creator>
<dc:creator>Mark S Link</dc:creator>
<dc:creator>Kathleen T Linta</dc:creator>
<dc:creator>Gregory M Marcus</dc:creator>
<dc:creator>Patrick M McCarthy</dc:creator>
<dc:creator>Nimesh Patel</dc:creator>
<dc:creator>Kristen K Patton</dc:creator>
<dc:creator>Marco V Perez</dc:creator>
<dc:creator>Jonathan P Piccini</dc:creator>
<dc:creator>Andrea M Russo</dc:creator>
<dc:creator>Prashanthan Sanders</dc:creator>
<dc:creator>Megan M Streur</dc:creator>
<dc:creator>Kevin L Thomas</dc:creator>
<dc:creator>Sabrina Times</dc:creator>
<dc:creator>James E Tisdale</dc:creator>
<dc:creator>Anne Marie Valente</dc:creator>
<dc:creator>David R Van Wagoner</dc:creator>
<dc:date>2023-12-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</dc:title>
<dc:identifier>pmid:38043043</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.017</dc:identifier>
</item>
<item>
<title>New insights into dietary cholesterol absorption</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38040795/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231204212342&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Dec 1. doi: 10.1038/s41569-023-00975-y. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38040795/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231204212342&v=2.17.9.post6+86293ac">38040795</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00975-y>10.1038/s41569-023-00975-y</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38040795</guid>
<pubDate>Fri, 01 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Jennifer Harman</dc:creator>
<dc:date>2023-12-01</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>New insights into dietary cholesterol absorption</dc:title>
<dc:identifier>pmid:38040795</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00975-y</dc:identifier>
</item>
<item>
<title>Cardiac imaging: focus on safety, optimal delivery, and risk stratification</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38038647/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231204212342&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 1;44(45):4725-4728. doi: 10.1093/eurheartj/ehad773.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38038647/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231204212342&v=2.17.9.post6+86293ac">38038647</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad773>10.1093/eurheartj/ehad773</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38038647</guid>
<pubDate>Fri, 01 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2023-12-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiac imaging: focus on safety, optimal delivery, and risk stratification</dc:title>
<dc:identifier>pmid:38038647</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad773</dc:identifier>
</item>
<item>
<title>Necessary Role of Ceramides in the Human Microvascular Endothelium During Health and Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38037825/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231204212342&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSION: These data suggest that despite differential downstream signaling between health and disease, NSmase-mediated ceramide formation is necessary for proper functioning of the human microvascular endothelium. Therapeutic strategies that aim to significantly lower ceramide formation may prove detrimental to the microvasculature.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Dec 1. doi: 10.1161/CIRCRESAHA.123.323445. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Elevated plasma ceramides and microvascular dysfunction both independently predict adverse cardiac events. Despite the known detrimental effects of ceramide on the microvasculature, evidence suggests that activation of the shear-sensitive, ceramide-forming enzyme NSmase (neutral sphingomyelinase) elicits formation of vasoprotective nitric oxide (NO). Here, we explore a novel hypothesis that acute ceramide formation through NSmase is necessary for maintaining NO signaling within the human microvascular endothelium. We further define the mechanism through which ceramide exerts beneficial effects and discern key mechanistic differences between arterioles from otherwise healthy adults (non-coronary artery disease [CAD]) and patients diagnosed with CAD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Human arterioles were dissected from discarded surgical adipose tissue (n=166), and vascular reactivity to flow and C2-ceramide was assessed. Shear-induced NO and mitochondrial hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) production were measured in arterioles using fluorescence microscopy. H<sub>2</sub>O<sub>2</sub> fluorescence was assessed in isolated human umbilical vein endothelial cells.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Inhibition of NSmase in arterioles from otherwise healthy adults induced a switch from NO to NOX-2 (NADPH-oxidase 2)-dependent H<sub>2</sub>O<sub>2</sub>-mediated flow-induced dilation. Endothelial dysfunction was prevented by treatment with sphingosine-1-phosphate (S1P) and partially prevented by C2-ceramide and an agonist of S1P-receptor 1 (S1PR1); the inhibition of the S1P/S1P-receptor 1 signaling axis induced endothelial dysfunction via NOX-2. Ceramide increased NO production in arterioles from non-CAD adults, an effect that was diminished with inhibition of S1P/S1P-receptor 1/sphingosine-1-phosphate receptor 3 signaling. In arterioles from patients with CAD, inhibition of NSmase impaired the overall ability to induce mitochondrial H<sub>2</sub>O<sub>2</sub> production and subsequently dilate to flow, an effect not restored with exogenous S1P. Acute ceramide administration to arterioles from patients with CAD promoted H<sub>2</sub>O<sub>2</sub> as opposed to NO production, an effect dependent on sphingosine-1-phosphate receptor 3 signaling.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: These data suggest that despite differential downstream signaling between health and disease, NSmase-mediated ceramide formation is necessary for proper functioning of the human microvascular endothelium. Therapeutic strategies that aim to significantly lower ceramide formation may prove detrimental to the microvasculature.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38037825/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231204212342&v=2.17.9.post6+86293ac">38037825</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323445>10.1161/CIRCRESAHA.123.323445</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38037825</guid>
<pubDate>Fri, 01 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Gopika SenthilKumar</dc:creator>
<dc:creator>Boran Katunaric</dc:creator>
<dc:creator>Zachary Zirgibel</dc:creator>
<dc:creator>Brian Lindemer</dc:creator>
<dc:creator>Maria J Jaramillo-Torres</dc:creator>
<dc:creator>Henry Bordas-Murphy</dc:creator>
<dc:creator>Mary E Schulz</dc:creator>
<dc:creator>Paul J Pearson</dc:creator>
<dc:creator>Julie K Freed</dc:creator>
<dc:date>2023-12-01</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Necessary Role of Ceramides in the Human Microvascular Endothelium During Health and Disease</dc:title>
<dc:identifier>pmid:38037825</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323445</dc:identifier>
</item>
<item>
<title>MINT trial signals potential benefit of liberal transfusion strategy in MI with anaemia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38036672/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231204212342&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Nov 30. doi: 10.1038/s41569-023-00969-w. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38036672/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231204212342&v=2.17.9.post6+86293ac">38036672</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00969-w>10.1038/s41569-023-00969-w</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38036672</guid>
<pubDate>Thu, 30 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2023-11-30</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>MINT trial signals potential benefit of liberal transfusion strategy in MI with anaemia</dc:title>
<dc:identifier>pmid:38036672</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00969-w</dc:identifier>
</item>
<item>
<title>PCI for stable angina</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38036671/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231204212342&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Nov 30. doi: 10.1038/s41569-023-00967-y. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38036671/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231204212342&v=2.17.9.post6+86293ac">38036671</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00967-y>10.1038/s41569-023-00967-y</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38036671</guid>
<pubDate>Thu, 30 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Gregory B Lim</dc:creator>
<dc:date>2023-11-30</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>PCI for stable angina</dc:title>
<dc:identifier>pmid:38036671</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00967-y</dc:identifier>
</item>
<item>
<title>Non-invasive ultrasound therapy for calcified aortic valve stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38036670/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231204212342&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Nov 30. doi: 10.1038/s41569-023-00968-x. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38036670/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231204212342&v=2.17.9.post6+86293ac">38036670</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00968-x>10.1038/s41569-023-00968-x</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38036670</guid>
<pubDate>Thu, 30 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2023-11-30</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Non-invasive ultrasound therapy for calcified aortic valve stenosis</dc:title>
<dc:identifier>pmid:38036670</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00968-x</dc:identifier>
</item>
<item>
<title>SELECT shows cardiovascular risk reduction with weight-loss drug semaglutide in people without diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38036669/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231204212342&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Nov 30. doi: 10.1038/s41569-023-00970-3. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38036669/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231204212342&v=2.17.9.post6+86293ac">38036669</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00970-3>10.1038/s41569-023-00970-3</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38036669</guid>
<pubDate>Thu, 30 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2023-11-30</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>SELECT shows cardiovascular risk reduction with weight-loss drug semaglutide in people without diabetes</dc:title>
<dc:identifier>pmid:38036669</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00970-3</dc:identifier>
</item>
<item>
<title>A very rare and unusual complication after a percutaneous patent foramen ovale closure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38036461/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231204212342&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 30:ehad800. doi: 10.1093/eurheartj/ehad800. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38036461/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231204212342&v=2.17.9.post6+86293ac">38036461</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad800>10.1093/eurheartj/ehad800</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38036461</guid>
<pubDate>Thu, 30 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Claudiu Ungureanu</dc:creator>
<dc:creator>Giuseppe Colletti</dc:creator>
<dc:creator>Jacques Auslender</dc:creator>
<dc:date>2023-11-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A very rare and unusual complication after a percutaneous patent foramen ovale closure</dc:title>
<dc:identifier>pmid:38036461</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad800</dc:identifier>
</item>
<item>
<title>Quality and transparency of clinical evidence for high-risk cardiovascular medical devices: a long way to go</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38036418/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231204212342&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 30:ehad786. doi: 10.1093/eurheartj/ehad786. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38036418/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231204212342&v=2.17.9.post6+86293ac">38036418</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad786>10.1093/eurheartj/ehad786</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38036418</guid>
<pubDate>Thu, 30 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Piotr Szymański</dc:creator>
<dc:creator>Rita Redberg</dc:creator>
<dc:date>2023-11-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Quality and transparency of clinical evidence for high-risk cardiovascular medical devices: a long way to go</dc:title>
<dc:identifier>pmid:38036418</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad786</dc:identifier>
</item>
<item>
<title>Macrophage P2Y6 receptor deletion attenuates atherosclerosis by limiting foam cell formation through phospholipase Cβ/store-operated calcium entry/calreticulin/scavenger receptor A pathways</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38036416/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231204212342&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Macrophage P2Y6R regulates phospholipase Cβ/store-operated calcium entry/calreticulin signalling pathway to increase scavenger receptor A protein level, thereby improving foam cell formation and atherosclerosis, indicating that the P2Y6R may be a potential therapeutic target for intervention of atherosclerotic diseases using P2Y6R antagonists including thiamine pyrophosphate.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 30:ehad796. doi: 10.1093/eurheartj/ehad796. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Macrophage-derived foam cells play a causal role during the pathogenesis of atherosclerosis. P2Y6 receptor (P2Y6R) highly expressed has been considered as a disease-causing factor in atherogenesis, but the detailed mechanism remains unknown. This study aims to explore P2Y6R in regulation of macrophage foaming, atherogenesis, and its downstream pathways. Furthermore, the present study sought to find a potent P2Y6R antagonist and investigate the feasibility of P2Y6R-targeting therapy for atherosclerosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The P2Y6R expression was examined in human atherosclerotic plaques and mouse artery. Atherosclerosis animal models were established in whole-body P2Y6R or macrophage-specific P2Y6R knockout mice to evaluate the role of P2Y6R. RNA sequencing, DNA pull-down experiments, and proteomic approaches were performed to investigate the downstream mechanisms. High-throughput Glide docking pipeline from repurposing drug library was performed to find potent P2Y6R antagonists.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The P2Y6R deficiency alleviated atherogenesis characterized by decreasing plaque formation and lipid deposition of the aorta. Mechanically, deletion of macrophage P2Y6R significantly inhibited uptake of oxidized low-density lipoprotein through decreasing scavenger receptor A expression mediated by phospholipase Cβ/store-operated calcium entry pathways. More importantly, P2Y6R deficiency reduced the binding of scavenger receptor A to CALR, accompanied by dissociation of calreticulin and STIM1. Interestingly, thiamine pyrophosphate was found as a potent P2Y6R antagonist with excellent P2Y6R antagonistic activity and binding affinity, of which the pharmacodynamic effect and mechanism on atherosclerosis were verified.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Macrophage P2Y6R regulates phospholipase Cβ/store-operated calcium entry/calreticulin signalling pathway to increase scavenger receptor A protein level, thereby improving foam cell formation and atherosclerosis, indicating that the P2Y6R may be a potential therapeutic target for intervention of atherosclerotic diseases using P2Y6R antagonists including thiamine pyrophosphate.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38036416/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231204212342&v=2.17.9.post6+86293ac">38036416</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad796>10.1093/eurheartj/ehad796</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38036416</guid>
<pubDate>Thu, 30 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Yehong Li</dc:creator>
<dc:creator>Mengze Zhou</dc:creator>
<dc:creator>Huanqiu Li</dc:creator>
<dc:creator>Chen Dai</dc:creator>
<dc:creator>Li Yin</dc:creator>
<dc:creator>Chunxiao Liu</dc:creator>
<dc:creator>Yuxin Li</dc:creator>
<dc:creator>Enming Zhang</dc:creator>
<dc:creator>Xinli Dong</dc:creator>
<dc:creator>Hui Ji</dc:creator>
<dc:creator>Qinghua Hu</dc:creator>
<dc:date>2023-11-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Macrophage P2Y6 receptor deletion attenuates atherosclerosis by limiting foam cell formation through phospholipase Cβ/store-operated calcium entry/calreticulin/scavenger receptor A pathways</dc:title>
<dc:identifier>pmid:38036416</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad796</dc:identifier>
</item>





























</channel>
</rss>